Trial Profile
Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2023 Status changed from suspended to discontinued. Reason the study was stopped: Per CS0139535 -submitter stated we can update status to Admin complete- low accrual reasoning.
- 22 Mar 2022 Planned End Date changed from 15 Feb 2022 to 15 Feb 2023.
- 22 Mar 2022 Planned primary completion date changed from 15 Feb 2022 to 15 Feb 2023.